Kyverna Therapeutics, Inc.
KYTX · NASDAQ
Market closed$7.45$0.010000 (+0.13%)After hours $7.50 · +0.67%
Key statistics
Previous close$7.44
Open$7.26
Day high$7.68
Day low$7.20
52-week high$13.67
52-week low$2.80
Market cap326.25M
Volume872.89K
Average volume1.21M
P/E ratio-2.27
Forward P/E—
EPS-3.28
Dividend yield0.00%
Market context
Why it moved
KYTX (Kyverna Therapeutics) edged slightly higher amid broader biotech market activity, with modest investor interest following its recent mention alongside other notable movers in the sector.
What is happening
Recent company-specific developments and publisher coverage.
24/7 Wall St. · July 10, 2026Kyverna Therapeutics Sinks 13%: Here’s WhyStock Titan · June 22, 2026Kyverna adds legal chief as it prepares for commercializationQuiver Quantitative · May 18, 2026Kyverna Therapeutics Appoints Greg Martini as Chief Financial Officer | KYTX Stock NewsQuiver Quantitative · April 21, 2026Kyverna Therapeutics Reports Positive Trial Results for Miv-cel in Stiff Person Syndrome, Highlighting Potential to Transform Treatment ParadigmSTAT · April 21, 2026Kyverna Therapeutics plans to submit cell therapy for stiff person syndrome for FDA approvalInvesting.com · April 20, 2026Kyverna reports positive 24-week data from myasthenia gravis trialInvesting.com · December 17, 2025Kyverna Therapeutics stock plunges after $100 million share offeringBioPharma Dive · December 15, 2025Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease Benzinga · June 3, 2026Kyverna Therapeutics Reports Phase 1 Data For Miv-Cel In Rheumatoid Arthritis, Showing Deep B-Cell Depletion And Potential Immune Reset At Week 36 Mt Newswire · May 18, 2026Kyverna Therapeutics Names Greg Martini CFO Benzinga · May 13, 2026JP Morgan Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $29 Benzinga · May 12, 2026Kyverna Therapeutics Q1 EPS $(0.66) Beats $(0.73) Estimate Benzinga · April 22, 2026Reported Earlier, Kyverna's Miv-Cel Meets All Primary And Secondary Endpoints In KYSA-8 Registrational Trial, Potentially First Approved Treatment For Stiff Person Syndrome Benzinga · April 22, 2026Kyverna Therapeutics (KYTX) Stock Surges 24% After Hours: Why Is It Moving? Benzinga · April 2, 2026Kyverna Therapeutics Enters Open Market Sale Agreement With Jefferies Dated March 27, 2025; Co. May Offer Up To $100M Of Common Stock Mt Newswire · March 26, 2026Kyverna Therapeutics Files $300 Million Mixed Shelf